Acute chest syndrome in the setting of SARS-COV-2 infections-A case series at an urban medical center in the Bronx.
Kerry A MorroneKaitlin StrumphMark J LiszewskiJenai JacksonMichael L RinkeEllen J SilverCaterina MinnitiJennifer DavilaWilliam B MitchellDeepa ManwaniPublished in: Pediatric blood & cancer (2020)
New York City has emerged as one of the epicenters of the SARS-COV-2 pandemic, with the Bronx being disproportionately affected. This novel coronavirus has caused significant respiratory manifestations raising the concern for development of acute chest syndrome (ACS) in patients with sickle cell disease (SCD). We report a series of pediatric SCD SARS-COV-2-positive patients admitted with ACS. SARS-COV-2-positive SCD patients, who did not develop ACS, were the comparison group. Hydroxyurea use (P-value = .02) and lower absolute monocyte counts (P-value = .04) were noted in patients who did not develop ACS. These preliminary findings need to be further evaluated in larger cohorts.
Keyphrases
- sars cov
- acute coronary syndrome
- respiratory syndrome coronavirus
- liver failure
- end stage renal disease
- respiratory failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- drug induced
- case report
- peritoneal dialysis
- hepatitis b virus
- aortic dissection
- endothelial cells
- coronavirus disease
- prognostic factors
- young adults
- intensive care unit
- sickle cell disease
- patient reported outcomes